|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
58,625,000 |
Market
Cap: |
1.59(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$22.72 - $35.59 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
93,505 |
106,505 |
124,343 |
450,780 |
Total Sell Value |
$3,194,796 |
$3,569,126 |
$4,091,741 |
$15,155,681 |
Total People Sold |
1 |
2 |
5 |
6 |
Total Sell Transactions |
5 |
7 |
11 |
37 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kolluri Krishna Kittu |
10% Owner |
|
2015-06-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,921,000) |
0 |
|
- |
|
New Enterprise Associates 11 Lp |
10% Owner |
|
2015-06-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,000,000) |
7,641,250 |
|
- |
|
Nea Partners 11 Lp |
10% Owner |
|
2015-06-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(921,000) |
0 |
|
- |
|
Nea Partners 11 Lp |
10% Owner |
|
2015-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
921,000 |
921,000 |
|
- |
|
Nea Partners 11 Lp |
10% Owner |
|
2015-06-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,000,000) |
7,641,250 |
|
- |
|
Sandell Scott D |
10% Owner |
|
2015-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
1,153,034 |
166,986 |
|
- |
|
Sandell Scott D |
10% Owner |
|
2015-06-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,921,000) |
0 |
|
- |
|
Schwabe Stefan K.f. |
Executive Vice President R&D |
|
2015-06-12 |
4 |
AS |
$18.27 |
$37,472 |
D/D |
(2,051) |
2,794 |
|
- |
|
Schwabe Stefan K.f. |
Executive Vice President R&D |
|
2015-06-11 |
4 |
AS |
$16.32 |
$59,521 |
D/D |
(3,631) |
4,845 |
|
- |
|
Bryan Jones W. |
VP of Business Development |
|
2015-03-30 |
4 |
AS |
$12.02 |
$80,647 |
D/D |
(6,712) |
67,980 |
|
- |
|
Bryan Jones W. |
VP of Business Development |
|
2015-03-30 |
4 |
OE |
$2.56 |
$17,183 |
D/D |
6,712 |
74,692 |
|
- |
|
Bryan Jones W. |
VP of Business Development |
|
2015-03-24 |
4 |
AS |
$12.00 |
$22,800 |
D/D |
(1,900) |
67,980 |
|
- |
|
Bryan Jones W. |
VP of Business Development |
|
2015-03-24 |
4 |
OE |
$2.56 |
$6,364 |
D/D |
1,900 |
69,880 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2015-03-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(6,000) |
1,101,000 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2015-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
438,573 |
|
- |
|
Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
|
2015-01-15 |
4 |
OE |
$2.56 |
$96,000 |
D/D |
37,500 |
107,306 |
|
- |
|
Bhatt Padmanabh P. |
SR VP of IP, CSO |
|
2015-01-05 |
4 |
OE |
$0.40 |
$14,600 |
D/D |
18,000 |
69,806 |
|
- |
|
Siebert John M |
Director |
|
2014-12-16 |
4 |
OE |
$4.24 |
$9,277 |
D/D |
2,188 |
19,563 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2014-08-25 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,250 |
1,250 |
|
- |
|
Khattar Jack A. |
President, CEO |
|
2014-08-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,750 |
431,436 |
|
- |
|
345 Records found
|
|
Page 14 of 14 |
|
|